Free Newsletter
Another Amylin investor group rebels
Free newsletter via e-mail
Tools
Now, Amylin Pharmaceuticals faces two dissident investor groups: Eastbourne Capital Management has joined Carl Icahn's group in backing a slate of director candidates, saying it has "lost confidence" in the San Diego company's management. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: